ERNA

1.36016.56%
MA

Michael Andreeff

Member of Scientific Advisory Board

Dr. Michael Andreeff, M.D. Ph.D., is Member of the Scientific Advisory Board of Captor Therapeutics Spolka Akcyjna from 2026. He has been the Member of Scientific Advisory Board at Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) (formerly known as Brooklyn ImmunoTherapeutics, Inc.) since May 21, 2021. He serves as Member of Scientific Advisory Board at Moleculin Biotech, Inc. since November 2024. He serves as Member of Scientific Advisory Board at Oncolyze, Inc. He serves as the Head of Automated Cytometry and Cell Sorter/Confocal Microscopy and Image Analysis NIH-funded Core Laboratory at The University of Texas M.D. Anderson Cancer Center (UTMDACC), Houston. Dr. Andreeff serves as a Program Leader Hemtology (CCSG), Attending Physician, Departments of Leukemia and Blood and Marrow Transplantation and Director of Research for Department of Blood and Marrow Transplantation. He is a Professor of Medicine, Paul and Mary Haas Chair in Genetics in Genetics and Chief, Section of Molecular Hematology and Therapy at the University of Texas M.D. Anderson Cancer CenterHouston, TX (MDACC). He is the Director of the NCI-CCSG Flow Cytometry/Cellular Imaging Core Facility. He is a Professor of Medicine, Stringer Professor for Cancer Therapy and Research. Dr. Andreeff is Professor of Medicine in the Leukemia and Stem Cell Transplantation Departments at the University of Texas MD Anderson Cancer Center. He has been at MD Anderson since 1990, when he joined as Chief of the Leukemia Service. He serves as Member of Scientific Advisory Board at Senti Biosciences Holdings, Inc. (formerly known as Senti Biosciences, Inc.) He has been a Member of Scientific Advisory Board at Aptose Biosciences Inc. since March 2015. He serves as a Member of Scientific Advisory Board at Aegera Therapeutics Inc. and Oncoceutics, Inc. He served as a Member of Nox-A12 Advisory Board at NOXXON Pharma N.V. He serves as a Member of Clinical Advisory Board at TetraLogic Pharmaceuticals Corporation. He has published more than 450 peer-reviewed papers, five books and 75 book chapters. His research interests include molecular biology, apoptosis, hematopoietic and mesenchymal stem cells, acute and chronic leukemias, gene therapy and molecular targets for tumor therapy. His research focuses on leukemia therapy, the leukemia microenvironment, stem cells and apoptosis and he has developed numerous agents that target regulators of apoptosis and signaling in leukemias: Bcl-2, IAP, MDM/p53, MAPK and FLT3-ITD families of proteins. His research encompasses basic mechanistic studies of drug action, preclinical studies in vitro and in vivo using PDX models and Phase I/II clinical trials in leukemia patients. He has received uninterrupted funding from the National Cancer Institute (NCI), serves as the Principal Investigator (PI) of a grant entitled The Therapy of AML and participates as a PI in research grants focused on leukemia, lymphoma, ovarian and breast cancer, among others. Dr. Andreeff was awarded the first German Society of Hematology and Oncology Visiting Professorship (1993-1994) and the Kind-Phillip-Award for Leukemia Research from German Society for Pediatric Oncology. Dr. Andreeff received his M.D. and Ph.D. degrees and first faculty appointment at the University of Heidelberg, Germany and Subsequently, he moved to the Memorial Sloan Kettering Cancer Center in New York in 1977, became head of the Leukemia Cell Biology and Hematopathology Flow Cytometry Laboratory, organized the first Clinical Cytometry Conference in 1986 and the first Molecular Cytogenetics Conference in 1990.

Positions